Volume 49, Issue 11 , Pages 1501-1505, November 2000
Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level☆
Abstract
Abnormal glucose metabolism and a high prevalence of diabetes have been reported in patients with primary and secondary hyperparathyroidism. We hypothesize that plasma intact parathyroid hormone (iPTH) level is a determinant of either insulin sensitivity or β-cell function. The study included 52 normotensive, healthy subjects with glucose tolerance. Insulin sensitivity and β-cell function were assessed using a hyperglycemic clamp. Fasting plasma iPTH was determined. The relationships between its level and insulin sensitivity index and β-cell function were examined. Insulin sensitivity index was inversely correlated with plasma iPTH level (r2 = .104, P = .020). The first phase insulin response was positively correlated with plasma iPTH level (r2 = .098, P = .023), but no correlation existed with the second phase insulin response. After adjusting for age, gender, ethnicity, and waist-to-hip ratio, plasma iPTH level was an independent determinant of insulin sensitivity index (P = .019). However, no independent relationship between plasma iPTH level and β-cell function (the first phase and second phase insulin response) was found. In normotensive, glucose-tolerant, and healthy subjects, plasma iPTH level accounts for 10.4% of the variation in insulin sensitivity index. For each pg/mL increment in plasma iPTH level, there is a decrease of 0.247 μmol/L/m2/min/pmol/L in insulin sensitivity index. Although the molecular basis of this relationship is not clear, our results indicate that plasma iPTH level is inversely correlated with insulin sensitivity index. Copyright © 2000 by W.B. Saunders Company
To access this article, please choose from the options below
☆ Supported in part by Grants No. MO1RR00865 from United States Public Health Service (USPHS) (to UCLA-General Clinical Research Center [GCRC]), National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK) RO1DK52337-01 (to K.C.C.), Diabetes Action Research and Education Foundation (to K.C.C.), and the American Diabetes Association (to K.C.C.).
PII: S0026-0495(00)09635-9
doi:10.1053/meta.2000.17708
© 2000 W.B. Saunders Company. All rights reserved.
Volume 49, Issue 11 , Pages 1501-1505, November 2000
